Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) insider Filip Janku sold 11,845 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $20.22, for a total value of $239,505.90. Following the completion of the sale, the insider directly owned 59,992 shares in the company, valued at $1,213,038.24. This trade represents a 16.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Filip Janku also recently made the following trade(s):
- On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total value of $642,600.00.
Monte Rosa Therapeutics Stock Performance
Shares of GLUE traded up $0.81 during trading hours on Thursday, hitting $21.66. The company had a trading volume of 1,768,259 shares, compared to its average volume of 1,328,242. The firm has a fifty day moving average price of $18.79 and a 200-day moving average price of $18.58. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -14.64 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a 52-week low of $4.12 and a 52-week high of $25.77.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC bought a new position in Monte Rosa Therapeutics during the fourth quarter valued at approximately $30,000. Nisa Investment Advisors LLC boosted its position in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Monte Rosa Therapeutics during the 4th quarter valued at about $63,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter valued at about $32,000. 79.96% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Guggenheim lowered their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Wall Street Zen downgraded Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $32.50.
Read Our Latest Analysis on GLUE
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.
The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.
Further Reading
- Five stocks we like better than Monte Rosa Therapeutics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
